Eli Lilly will report first quarter earnings before the bell. Here's what Wall Street expects
Eli Lilly is set to report first-quarter earnings, with Wall Street expecting strong results driven by sales of its GLP-1 drugs Zepbound and Mounjaro. Analysts project Zepbound to generate $4.04 billion in sales and Mounjaro $7.26 billion worldwide, reflecting the company's leading position in the obesity and diabetes markets. Although the newly launched obesity pill, Zepbound, won't be reflected in the quarter's results, its rollout and competitive positioning are expected to be key topics on the earnings call.
Opening excerpt (first ~120 words) tap to expand
Eli Lilly is slated to report first-quarter earnings before the bell on Thursday, in one of the most closely watched reports across the healthcare sector. Here's what Wall Street is expecting, based on a survey of analysts by LSEG: Earnings per share: $6.66 adjusted expectedRevenue: $17.62 billion expectedDemand for the company's blockbuster obesity drug Zepbound and diabetes counterpart Mounjaro has helped fuel several solid quarters for Lilly, which holds the majority market share in the booming GLP-1 space. Analysts expect Zepbound to rake in overall sales of $4.04 billion, with $3.98 billion coming from the U.S., according to StreetAccount estimates. Meanwhile, they expect Mounjaro to book worldwide sales of $7.26 billion, including U.S.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Business.
Discussion
0 commentsMore from CNBC — Business
